BioTuesdays

Category - Markets

Genfit Logo

Roth starts Genfit at buy; PT €116

Roth Capital Partners launched coverage of Genfit (PSE:GNFT) with a “buy” rating and 12-month price target of €116. The stock closed at €22.09 on Dec. 20. “A spearhead in NASH drug development, Paris-based Genfit is...

Moleculin Logo

Roth starts Moleculin Biotech at buy; PT $8

Roth Capital Partners initiated coverage of Moleculin Biotech (NASDAQ:MBRX) with a “buy” rating and $8 price target. The stock closed at $1.69 on Dec. 20. “Our Moleculin bull thesis is based solely on its liposomal...

ConforMIS

BTIG ups ConforMIS to buy; PT $4

BTIG upgraded ConforMIS (NASDAQ:CFMS) to “buy” from “neutral” with a price target of $4. The stock was quoted at $2.58, up 30 cents, in afternoon trading on Dec. 20. ConforMIS designs and manufactures customized knee...

Organigram

Mackie ups Organigram price target to $5

Mackie Research raised its price target for Organigram Holdings (TSX:OGI) to $5 from $4 after the company completed a $57.5-million offering of units at a price of $3.50 a unit. The stock closed at $3.70 on Dec. 18...

Leerink Logo

Leerink outlines 2018 outlook of healthcare shares

Leerink is recommending that healthcare investors, after a market-beating 2017, look for ways to keep up with what will likely be a strong broader stock market in 2018. “We encourage use of higher-beta healthcare and...

Catalyst

Ladenburg ups Catalyst Bioscience PT to $14.25

Ladenburg Thalmann raised its price target for Catalyst Biosciences (NASDAQ:CBIO) to $14.25 from $11 after the company modified the Phase 1/2 protocol of CB 2679d that should accelerate the timeline to initiation of a...

Restoration Robotics

Roth starts Restoration Robotics at buy

Roth Capital Partners launched coverage of Restoration Robotics (NASDAQ:HAIR) with a “buy” rating and price target of $7.50. The stock closed at $4.86 on Dec. 15. Restoration is focused on developing and commercializing...

GlycoMimetics

Stifel ups GlycoMimetics price target to $23

Stifel raised its price target for GlycoMimetics (NASDAQ:GLYC) to $23 from $17 after the company presented incremental Phase 1/2 data for GMI-1271 in both relapsed/refractory (R/R) and newly-diagnosed AML patients. The...

scPharmaceuticals

Leerink starts scPharmaceuticals at OP; PT $20

Leerink launched coverage of scPharmaceuticals (NASDAQ:SCPH) with an “outperform” rating and $20 price target. The stock closed at $14.92 on Dec 11. “The lead product, Furoscix (furosemide, diuresis for heart failure...

Diplomat Pharmacy

Leerink ups Diplomat Pharmacy to OP; PT to $23

Leerink upgraded Diplomat Pharmacy (NYSE:DPLO) to “outperform” and raised its price target to $23 from $20 after recent investor meetings with the company’s management and after considering several new developments. The...